Vmbook Online ordering
Bioheart Inc
Sure, I'd be happy to help you with information about Bioharvest Sciences Inc. (BHRTV), a publicly traded biotechnology company listed on the OTCQB, the Venture Market of the OTC Bulletin Board, and the Tel Aviv Stock Exchange.
Organization Information : Bioharvest Sciences Inc., a biotech company developing novel, natural therapies for cancer and other illnesses, announced that it will be listed on the OTCQB, the Venture Market of the OTC Bulletin Board, under the symbol "BHRTV" on June 15, 2021.
Bioharvest Sciences, based in Vancouver, Canada, is a biotechnology firm developing natural therapies for cancer and other diseases. Their primary technology involves cellular agriculture, growing cells in bioreactors that are often used in the pharmaceutical industry to manufacture medications. This cutting-edge approach allows them to produce bioactive chemicals without harming animals or damaging the environment. Bioharvest's goal is to create treatments that will transform how we treat diseases, enhancing people's quality of life.
Products: Bioharvest Sciences is developing novel medicines for multiple illnesses, including cancer, using their cutting-edge technology. They have successfully created various immune-related treatments that have shown positive benefits in early trials. These therapies aim to strengthen the body's immune system to combat cancer cells effectively.
Earnings: Bioharvest Sciences only recently became a publicly traded company; therefore, earnings data is limited. Nevertheless, the corporation has received significant capital through fundraising rounds, including a $22.5 million private placement round in 2020.
Agreements and Collaborations: Bioharvest Sciences has formed significant partnerships with esteemed institutions and organizations. They collaborate with the Hebrew University of Jerusalem and the University of California, Los Angeles (UCLA), for research and development. Additionally, they have teamed up with Deloitte to assist with data management and other services.
Developments: The company has made significant strides in advancing its technology and treatments, including the successful completion of a Phase 0 clinical trial in 2020 and the start of a Phase 1 clinical trial in 2021 for its lead therapeutic candidate, BHR-001. Furthermore, Bioharvest has begun investigating the practical applications of its patented Evolve technology in various medical conditions, such as cancer and neurodegenerative diseases.
Bioharvest Sciences is dedicated to creating new, natural therapies to improve the lives of people battling cancer and other illnesses. The company's ground-breaking technology allows it to produce medications without harming animals or harming the environment. They have built a promising product pipleine, received considerable capital, and formed crucial collaborations with respected institutions. While earnings are still limited due to their relatively recent listing as a public company, they have made significant strides in advancing their technology and therapies.
Overall, Bioharvest Sciences seems a fascinating biotechnology company with significant potential for development. They have created cutting-edge technology that could transform how we approach drug development and therapy. While they are still in the early phases of earnings, their significant partnerships and fundraising rounds show promise.